Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies – Business Wire

Posted on by

TOKYO & CAMBRIDGE, England--(BUSINESS WIRE)--Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) and Wren Therapeutics Ltd. (Headquarters: Cambridge, UK, Wren) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target -synuclein for the potential treatment of synucleinopathies including Parkinsons disease and dementia with Lewy bodies.

Wren possesses a novel network kinetics drug discovery platform that precisely quantifies the effects of small molecules on the protein misfolding and aggregation pathway that causes neurodegenerative diseases. Wrens approach to synucleinopathies is focused on identifying novel small molecules that selectively control the aggregation process of -synuclein, which is associated with the onset and progression of these diseases. The collaboration will use Wrens network kinetics drug discovery platform, alongside Eisais extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: We are delighted to have formed this collaboration with Eisai, a company with a distinguished track record and company-wide commitment to providing innovative treatments for patients suffering from neurodegenerative diseases. We believe that by combining our unique, predictive and quantitatively driven platform with Eisais deep expertise in neurology, we can together advance highly differentiated small molecules targeting -synuclein for the treatment of debilitating protein misfolding disorders such as Parkinsons disease.

Dr. Teiji Kimura, Vice President, Chief Discovery Officer of the Eisai Neurology Business Group, commented: Synucleinopathies such as dementia with Lewy bodies and Parkinsons disease represent a significant unmet medical need due to the lack of any effective disease-modifying treatments. The accumulation of -synuclein oligomers with protein misfolding is an important hallmark of these diseases. The Wren team, with its world-renowned founding scientists, is pioneering a new and fundamentally different approach to addressing protein misfolding diseases. By integrating capabilities across both companies we expect this exciting collaboration to be uniquely successful in identifying novel disease-modifying therapeutics for patients suffering from dementia with Lewy bodies, Parkinsons disease and related disorders.

About Wrens novel network kinetics drug discovery platformWrens proprietary network kinetics drug discovery platform enables an entirely new approach to drug discovery, designed specifically to address the unique challenges associated with protein misfolding diseases. The kinetics-based approach solves for the distinct molecular reaction network that underlies each misfolding disease and produces a fully predictive, quantitative map of the network and its dynamics. The platform identifies the optimum intervention points in the network to reduce the populations of toxic misfolded and aggregated species, and subsequently makes it possible to identify and optimise molecules with the desired kinetic inhibitory activity.

About SynucleinopathiesSynucleinopathies are neurodegenerative diseases characterised by the aberrant misfolding and aggregation of -synuclein in neurons and glial cells. Synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).

About Eisai Co., Ltd.Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as giving first thought to patients and their families and to increasing the benefits health care provides, which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.For further information on Eisai Co., Ltd., please visit https://www.eisai.com.

About Wren Therapeutics Ltd.Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden), focused on drug discovery and development for protein misfolding diseases. Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process. Wren's predictive, quantitative platform is built on concepts from the physical sciences and is a fundamental shift from the descriptive, qualitative methods of traditional biology, which have failed to successfully address these complex systems. Wren is using its unique approach to develop a broad pipeline of therapeutics for protein misfolding diseases.For further information on Wren, please visit http://www.wrentherapeutics.com

Continue reading here:
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies - Business Wire

New Targeted Approach Could Prevent Toxicities Associated with Neurological Gene Therapies – BioSpace

Posted on by

Researchers from Penn Medicine have developed a new targeted approach that modifies viral vectors and inhibits toxicities in the sensory neurons of dorsal root ganglia (DRG) that commonly occur following the use of gene therapy for neurological diseases.

This strategy will likely have several important research and clinical implications, as investigators in the field have worked tirelessly for years to develop safer and more effective gene therapies for neurological disorders. We believe that this new approach could improve safety in gene therapy universally, said lead author Juliette Hordeaux, DVM, Ph.D., senior director of Translational Research in Penns Gene Therapy Program, in a statement.

Many gene therapies use viral vectors, but these vectors can have adverse neurological effects. While these toxicities have not yet been observed in humans, nonhuman primate studies using adeno-associated viral (AAV) vectors to deliver corrected genes via the spinal cord fluid have shown issues of axonal degeneration in spinal cord and peripheral nerve tracts. In these studies, the cause of the issues led back to the DRG, comprising a cluster of neural cells found on the outside of the spinal cord that are responsible for delivering sensory messages.

In a recent paper published in Science Translational Medicine, Dr. Hordeaux and colleagues found a way of modifying these vectors so they ultimately avoid these dangerous side effects. They first found that the toxicities appear to come from overexpression of a transgene in cells in the DRG.

The researchers altered a transgene with a microRNA target that was designed to reduce transgene expression levels in the DRG. Ultimately, this modification eliminated over 80% of the transgene expression and resulted in drastic toxicity reduction in the studied primates

We believe it is a safe, straightforward way to ameliorate the safety of AAV therapy for the central nervous system, said Hordeaux about the studied modification. This approach could be used to design other gene therapy vectors to repress transgene expression in the cell types that are affected by the toxicity and not others, which is critical, because you need the expression everywhere else to effectively treat the disorder.

Senior author of the paper was gene transfer expert James M. Wilson, MD, Ph.D., professor of Medicine and Pediatrics in Penns Perelman School of Medicine. Dr. Wilson, who left Solid Biosciences two years ago. Dr. Wilson has been discussing the potential adverse neurological effects of AAV vectors for several years.

Drs. Hordeaux and Wilson injected vectors with and without a microRNA target miRNA183 in mice and primates in the new study. The administration of unaltered AAV vectors led to robust delivery of the gene into target tissue as well as toxicities in DRG neurons. These effects occurred without impacting transduction in elsewhere in the brain, according to histological analyses conducted up to 90 days later.

The authors of the study suggest the toxicity of DRGs likely occur in a gene therapy relying on high vector doses or direct vector delivery into the fluid of the spinal cord. We were concerned about the DRG pathology that was observed in most of our nonhuman primate studies, noted Wilson. This modified vector shows great promise to reduce DRG toxicity and should facilitate the development of safer AAV-based gene therapies for many central nervous system diseases.

Read more from the original source:
New Targeted Approach Could Prevent Toxicities Associated with Neurological Gene Therapies - BioSpace

Clubs may need to hire neurologists as part of plans to combat concussion – The Guardian

Posted on by

Football clubs may be required to add neurologists to their medical teams as part of plans to confront concussion in the sport.

Trials of concussion substitutes are expected to be authorised by the games rule-making body, Ifab, next month as the authorities attempt to get to grips with the risk of brain injuries.

But the complexities of implementing a plan, including the possible recruitment of extra medical staff and the logistical and legal challenges around the trials, may mean they are not implemented until the 2021-22 season.

The recent diagnosis of dementia in Sir Bobby Charlton, the death of Nobby Stiles and campaigning by families of former players with dementia have returned focus to the risks of neurodegenerative disease.

On Wednesday the Professional Footballers Association announced it would launch a working group including relatives of former players to help refine its support provisions for former players with neurodegenerative conditions.

There remains great uncertainty over how to best limit the risk in contemporary generations of players, however. Action was taken this year in England, Scotland and Northern Ireland to ban heading in training for under-12s, with some limitations for older children too.

But adults face no limitations on heading practice, with Gary Lineker coming out in favour of restrictions. Theres absolutely no reason to head the ball in training, the former England striker tweeted.

Players face further risks during matches and in December Ifab plans to confirm a protocol that would allow teams extra substitutes in the event of an apparent concussion. If the protocol is approved at Ifabs annual business meeting, competitions will be invited to apply to trial the protocols with campaigners hoping these could begin this season.

Under the protocol, club doctors would have three minutes to evaluate a player on the field before deciding whether to substitute them, though that period could be longer if the player were to leave the pitch.

There are concerns that would be too short a time to properly evaluate the player and it is understood such considerations have meant the Premier League and Football Association are reluctant to commit to implementing the protocol immediately after it is agreed.

The recruitment of a specialist concussion team could be one of the solutions, according to the Ifab secretary, Lukas Brud. Before the protocols can be implemented, logistical and legal frameworks need to be put in place, amendments to the regulations need to be agreed then approved, he said, describing the hurdles to clear before trials can begin.

We are not encouraging the introduction mid-season, only allowing it. It will be down to individual competitions. Will it require a concussion team, a neurologist on hand? These are the questions competitions will ask and they will be required to feed back on challenges.

The announcement of the PFAs neurodegenerative disease working group will also bring extra focus on the plight of former players and their families with these conditions.

After receiving criticism over a perceived lack of support for members with dementia, including from Stiless son John, the players union said the group would help guide the PFA with decisions regarding the support and protection of former and current footballers.

Previously our support has predominantly been based on financial assistance and advice, it said. Now, with the guidance of our working group, we want to ensure a more holistic support system is available for former footballers and their families.

In another development lawyers have called for former players to come forward with their stories before potential legal action. The personal injury specialists John Foy and James Byrne, alongside Nick De Marco QC, are representing a group of players and hope to establish whether clubs and governing bodies have taken timely and proper steps to prevent the injuries we are seeing, according to De Marco.

The litigation is still in its early stages and we still want to hear from professional sports players, De Marco said. By bringing this case we hope not only to provide our clients with adequate compensation to pay for the future medical treatment and care they will inevitably need but also to bring about much-needed reform.

Read the original post:
Clubs may need to hire neurologists as part of plans to combat concussion - The Guardian

The dementia that can be cured – The Guardian

Posted on by

When John Abraham began to lose his mind in late 2019, his family immediately feared the worst. Abraham had enjoyed robust health throughout retirement, but now at 80 he suddenly found himself struggling to finish sentences.

I would be talking to people, and all of a sudden the final word wouldnt come to mind, he remembers. I assumed this was simply a feature of ageing, and I was finding ways of getting around it.

But within weeks, further erratic behaviours started to develop. Abrahams family recall him often falling asleep mid-conversation, he would sometimes shout out bizarre comments in public, and during the night he would wake up every 15 minutes, sometimes hallucinating.

Patients can go from being in a nursing home, unable to communicate, to returning to work

To his son Steve, the diagnosis seemed inevitable, one which all families dread. I was convinced my dad had dementia, he says. What I couldnt believe was the speed at which it was all happening. It was like dementia on steroids.

Dementia is not just one disease it has more than 200 different subtypes. Over the past decade neurologists have become increasingly interested in one particular subtype, known as autoimmune dementia. In this condition, the symptoms of memory loss and confusion are the result of brain inflammation caused by rogue antibodies known as autoantibodies binding to the neuronal tissue, rather than an underlying neurodegenerative disease. Crucially this means that unlike almost all other forms of dementia, in some cases it can be cured, andspecialist neurologists have become increasingly adept at both spotting and treating it.

At the John Radcliffe hospital, University of Oxford, neurologist Sarosh Irani is one of the worlds leading experts in treating neurological conditions caused by a malfunctioning immune system. When Abraham was admitted under his care in early January 2020 following a seizure, Irani soon realised that the source of his problems was an autoantibody which targeted a protein in the brain named LGI1.

The main telltale clue was the speed of onset, one of the key distinguishing features of autoimmune dementia. The symptoms usually come on very quickly, Irani says. Over a few weeks or months, patients develop memory problems, and change their behaviour and personality. Patients with neurodegenerative forms of dementia can develop movement disorders or seizures, but this typically happens later in the illness once degeneration has set in. In autoimmune dementia, these are early problems.

Abraham underwent a treatment called plasma exchange, which aims to wash the blood of the disease-causing antibodies. The impact was almost instant. For me it caused a complete transformation, in one or two days, he says. My family came in to see me in the hospital, and they just looked at each other in amazement.

Such dramatic improvements are often reported as soon as treatment which can also include steroids and other immunotherapies begins. Patients can go from being in a nursing home, unable to communicate, to returning to work, being able to drive again, says Eoin Flanagan, a neurologist at the Mayo Clinic in Rochester, Minnesota, one of a handful of centres in the world along with Iranis research group, that is actively studying autoimmune dementia.

This is one reason why the condition, though rare Mayo Clinic neurologist Sean Pittock estimates that it makes up less than 5% of all dementia cases is so important to identify. The data available suggests that it is often missed. Among autoimmune dementia patients who were successfully treated at the Mayo Clinic between 2002 and 2009, 35% had been initially misdiagnosed with either Alzheimers or Creutzfeldt-Jakob disease.

A lot of patients over 60 are misdiagnosed, says Flanagan. Thats a concern because if you miss these cases, youre committing them to a presumed neurodegenerative course when they could respond to immunotherapy, and their symptoms resolve.

But autoimmune dementia is also an illustration of a broader trend. Over the past 15 years, treatable diseases have been identified across an entire spectrum of neurological illnesses from epilepsy to multiple sclerosis and psychiatry, all caused by autoantibodies binding to different parts of the brain and central nervous system.

Its become one of the most exciting areas of neurology, says Irani. There are subgroups within all these illness groups that have very treatable diseases. If youre a dementia doctor, a small percentage of your patients will have this condition, the same if youre a psychiatrist or a multiple sclerosis doctor. And with these patients you can actually directly treat the underlying cause by suppressing the immune system.

In October 2019, another patient was admitted to the John Radcliffe hospital.Pippa Carter, aged 19, had just begun an English literature degree at the University of Leeds when she noticed that her vision seemed to be strangely distorted.

I would be in lectures and I was really struggling to focus with my eyesight and with concentration in general, she says. I was trying to audition for a university play, and I had to stop because I couldnt really read at all. Initially, I thought it was just nerves because I was starting a new chapter in life.

Within weeks, she found herself unable to get her words out properly, before she was taken to hospital after suffering a large seizure. Just like Abraham, it was the speed of her decline which alerted doctors to a potential autoimmune cause. Within a week she was hallucinating, shouting things, remembers Irani. In her hospital room, which she was in for several weeks, she drew these bizarre childlike pictures on the wall, like the sorts of things a four-year-old would draw. It was like something was causing her to regress in her behaviour.

Carter was suffering from a neuropsychiatric syndrome caused by an autoantibody binding to the brains NMDA receptors, proteins which play a key role in learning and memory formation. Soon after she began treatment, first with steroids, and then an immunotherapy called rituximab, she began to improve. Now more than a year on, she is hoping to resume her university studies soon.

Since 2004, scientists have been steadily discovering the autoantibodies behind these various neurological conditions, making it possible for clinics to test for them. Irani says that so far they have discovered approximately 25, with one or two new autoantibodies detected every year. There are probably many more out there still, he says. Were not at the tip of the iceberg, but I think were probably nowhere near the base either.

Precisely what stimulates the body to produce these autoantibodies remains unclear, but it is thought that there can be a variety of environmental triggers ranging from viral infections to tumours, along with an underlying genetic susceptibility.

Due to the number of patients who can be successfully treated, specialists are looking to raise awareness of the importance of keeping an eye out for them. Its really a not-to-miss set of conditions, says Irani. Our clinic runs a diagnostics lab where we receive UK-wide samples for many of these diseases. One in 100 are positive, and these patients clearly get better with steroids and similar medications.

There are signs that the interest is growing. In November 2019, data was published from the first clinical trial looking at the effectiveness of different treatments for patients with a type of epilepsy caused by LGI1 autoantibodies. Two more trials are under way looking at new experimental therapies aimed at trying to stop the body from producing these damaging antibodies.

Irani is hoping that this will yield many benefits in years to come. Theres definitely an under-recognition of these conditions, he says. But as the field continues to expand, there will be more and more of these patients who get picked up. Im sure that if you look hard enough in acute psychiatry wards, and in nursing homes, there are patients out there with treatable conditions who are being missed.

Go here to read the rest:
The dementia that can be cured - The Guardian

62 persons had COVID-related stroke in Bengaluru from June to August – The Hindu

Posted on by

As many as 62 people diagnosed with COVID-19 suffered a stroke in the city during the infection between June and August. Of these 16% died in hospital, a study by doctors from St Johns Medical College Hospital has revealed.

The multi-centre retrospective study from 13 hospitals has been accepted for publication in the International Journal of Stroke, the official publication of the World Stroke Organization.

A stroke is the sudden onset of neurological deficit due to vascular causes.

Thomas Mathew, Professor and Head of the department of Neurology at St. Johns Medical College Hospital, who is the principal investigator of the study, told The Hindu that COVID-19 related strokes (CORS) are associated with increased mortality and morbidity.

We found that mortality among the 62 CORS was high compared to the non-COVID-19 strokes diagnosed during the corresponding period last year. While 111 suffered a stroke from June to August last year according to St. Johns Stroke Registry, no death was reported, he said.

Of the 62 CORS, 60 (97%) patients had ischemic strokes while two (3%) had haemorrhagic strokes. A majority of them (59.7%) had a bad stroke wherein the large artery was blocked.

The mean age of patients was 55.66 with a standard deviation of 13.20 years. While 34 (77.4%) were male patients, 26 % (16/62) of patients did not have any conventional risk factors for stroke.

Attributing CORS in those without risk factors to inflammation triggered thrombosis and damage to endothelium due to COVID-19, Dr. Mathew said: However, in the remaining 46 patients, 54.8% had diabetes, 61.3% had hypertension, 8% had coronary artery disease, and 4.8% had atrial fibrillation.

City-based neurologists said they were seeing various neurological manifestations of COVID-19.

Amit Kulkarni, consultant neurologist at SPASRH Hospital, said with COVID-19 the problem was not just the sequelae of lung involvement but also varied other aspects like clotting occurring in the arteries of the lung, arteries of the brain, veins in the leg and venous sinuses in the brain, causing deep vein thrombosis, pulmonary embolism, arterial and venous strokes in the brain.

What is also unusual about this disease is the varied immunological manifestations like limp paralysis of arms and legs (Guillian Barre syndrome), facial paralysis with asymmetry, cranial nerve palsies causing double vision, drooping of the eye and muscle involvement (myositis). We have noted quite a few peripheral nerve palsies presenting with foot drop in patients recently affected or recovering from COVID (inability to extend the foot) where the other routine blood work is negative for any connective tissue disease and there is no spinal/peripheral cause of nerve compression, he said.

G.T. Subhas, former president of Bangalore Stroke Support Group and former director of Bangalore Medical College and Research Institute said the common symptoms of stroke can be remembered by Facial Drooping, Arm Weakness, Speech Difficulties and Time to reach a stroke ready hospital abbreviated as FAST.

Both during and post COVID-19, people should not ignore warning signs such as dizziness, sudden weakness in limbs and difficulty in speaking or understanding words. Patients should reach the hospital within three or four hours of the stroke. The earlier the patient is rushed to a hospital, the better the outcome, he added.

Hospitals that were part of the study included St. Johns, Bengaluru Medical College and Research Institute, Manipal Hospitals, Sakra, Apollo, M.S. Ramaiah, Satya Sai Institute of Higher Medical Sciences, and Narayana Health.

Originally posted here:
62 persons had COVID-related stroke in Bengaluru from June to August - The Hindu

Interventional Neurology Devices Market to 2020 Review With Current Demand and Forecasts | COVID-19 Analysis – PRnews Leader

Posted on by

Precisionbusinessinsights Research offers an overarching research and analysis-based study on the globalInterventional Neurology Devices market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global Interventional Neurology Devices market. The researchers and analysts who have prepared the report used an advanced research methodology and authentic primary and secondary sources of market information and data. Readers are provided with clear understanding on the current and future situations of the global Interventional Neurology Devices market based on revenue, volume, production, trends, technology, innovation, and other critical factors.

Get the Sample of this[emailprotected]

https://www.precisionbusinessinsights.com/request-sample/?product_id=17677&utm_source=3w&utm_medium=24

The report offers an in-depth assessment of key market dynamics, the competitive landscape, segments, and regions in order to help readers to become better familiar with the global Interventional Neurology Devices market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the global Interventional Neurology Devices market. Importantly, it allows players to gain deep insights into the business development and market growth of leading companies operating in the global Interventional Neurology Devices market. Players will also be able to know about future market challenges, distribution scenarios, product pricing changes, and other related factors beforehand.

Interventional Neurology Devices Market Competition

Medtronic plc) (Ireland), Stryker Corporation (U.S.), Depuy Synthes (Johnson and Johnson Services Inc.) (U.S.),Abbott Laboratories (U.S.), Terumo Corporation (Japan),Bayer AG (Germany), Boston Scientific, Corporation (U.S.), and Penumbra, Inc. (U.S.)

Based on the product type, Global Marketsegmented into the following:

Based on the technology type, Global Marketsegmented into the following:

Based on the indication, Global Marketis segmented into the following:

Based on the end user, Global Market segmented into the following:

Table of ContentsExecutive Summary:It includes key trends of the global Interventional Neurology Devices market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the global Interventional Neurology Devices market based on production and revenue.

Production and Consumption by Region:It covers all regional markets focused in the research study. It discusses about prices and key players besides production and consumption in each regional market.

Key Players:Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the global Interventional Neurology Devices market.

Market Segments:This part of the report discusses about product type and application segments of the global Interventional Neurology Devices market based on market share, CAGR, market size, and various other factors.

Research Methodology:This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Get Customized Report @

https://www.precisionbusinessinsights.com/request-customisation/?product_id=17677?utm_source=3w&utm_medium=24

The report is a perfect example of a detailed and meticulously prepared research study on the global Interventional Neurology Devices market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the global Interventional Neurology Devices market.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Read the original here:
Interventional Neurology Devices Market to 2020 Review With Current Demand and Forecasts | COVID-19 Analysis - PRnews Leader

Neurology Software Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications – AlgosOnline

Posted on by

A recent research on ' Neurology Software market', now available with Market Study Report, LLC, is a thorough study on the latest market trends prevailing in the global business sphere. The report also offers important details pertaining to market share, market size, profit estimations, applications and statistics of this industry. The report further presents a detailed competitive analysis including growth strategies adopted by key players of the industry.

The research report on Neurology Software market encloses a complete examination of present and future scenario of this industry domain. It mentions the growth driving factors and opportunities which will help in industry expansion, as well as the challenges that will hamper the market growth.

Request a sample Report of Neurology Software Market at:https://www.marketstudyreport.com/request-a-sample/2972390?utm_source=algosonline.com&utm_medium=SP

The report offers historic as well as current data on various market segmentations to determine key products, applications, and end-users impacting the business revenue. It also highlights and market share and growth rate of the industry over the analysis period. Besides, the study contains pricing models and consumption patterns of this business space.

Other vital pointers in the Neurology Software market report:

Ask for Discount on Neurology Software Market Report at:https://www.marketstudyreport.com/check-for-discount/2972390?utm_source=algosonline.com&utm_medium=SP

Comprehensive assessment of all opportunities and risks in the Neurology Software market.

This exclusive study addresses key questions for stakeholders in the Neurology Software Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/world-neurology-software-market-research-report-2025-covering-usa-europe-china-japan-india-south-east-asia-and-etc

Related Reports:

1. World Data Quality Tools Market Research Report 2025 (covering USA, Europe, China, Japan, India, South East Asia and etc)Read More: https://www.marketstudyreport.com/reports/world-data-quality-tools-market-research-report-2025-covering-usa-europe-china-japan-india-south-east-asia-and-etc

2. World Antivirus Software Market Research Report 2025 (covering USA, Europe, China, Japan, India, South East Asia and etc)Read More: https://www.marketstudyreport.com/reports/world-antivirus-software-market-research-report-2025-covering-usa-europe-china-japan-india-south-east-asia-and-etc

Read More Reports On: https://www.marketwatch.com/press-release/car-airbag-market-size-2020-top-manufacturers-industry-share-regional-analysis-types-and-applications-and-forecasts-to-2025-2020-10-16?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/electron-microscope-sample-preparation-market-share-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2026-2020-10-16?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

View post:
Neurology Software Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications - AlgosOnline

How COVID-19 Influences Allergies, Neurology, and Sleep – Contagionlive.com

Posted on by

From sleep to neurologic conditions, to better food allergy care and worse respiratory outcomes, coronavirus 2019 (COVID-19) has been more impactful to every field of medicine this year than any disease in recent memory.

Courtesy of sister publicationHCPLive, here is some new research from this last week which illuminates COVID-19s effect on patients across non-infectious disease specialties.

COPD Linked to Three-Fold Greater Mortality Risk in Severe COVID-19 Patients

The prevalence of comorbid chronic obstructive pulmonary disease (COPD) among patients hospitalized with COVID-19 is actually lower than its presence in the general population, according to a new observational cohort analysis presented at the CHEST 2020 Annual Meeting this weekend.

A pair of investigators reported that just 5% of observed patients hospitalized with COVID-19 suffered from COPDversus significantly greater rates of cardiometabolic disease among the most severely ill patients.

Their analyses included 22 studies from 8 countries including 11,000-plus patients hospitalized with COVID-19.

Patients with COPD faced a three-fold greater risk of mortality (odds ratio [OR], 3.23; 95% CI, 1.59 6.57;P<.05) than those without.

Investigators also found that smoking was present in 37% of COVID-19 patientsyet patients who smoked faced only a 52% worsened risk of disease severity (OR, 1.52; 95% CI, 0.81 2.87;P= .20).

Virtually Supported Home Peanut Introduction is Viable Option

A new report detailed the first known use of a virtually-supported home peanut introduction in infant patients at risk of developing peanut allergy. The program, conducted in April, could provide means to continue crucial, timely peanut allergy care during the pandemic.

Investigators noted that no reactions were reported during the assessed virtual food introduction process, which they considered to be consistent with the current evidence that anaphylaxis is rare and non-threatening with first ingestion in infancy.

Thus, they emphasized that mild reactions can generally be managed with antihistamine and/or observation.

Even before COVID-19, lack of allergist resources presented significant barriers to the introduction of peanut to at-risk patients where there was hesitance, they wrote. Virtually supported introduction may represent a future option after COVID-19 to improve access for patients who live in remote areas, or otherwise have limited access to allergists, or for clinicians with overburdened clinics.

COVID-19 Linked to Several Neurological Disorders

Data from a prospective study conducted by investigators from the NYU Langone Grossman School of Medicine showed patients with COVID-19 may be at risk for developing new neurologic disorders.

The study observed that 13.5% of patients hospitalized with COVID-19 during the study timeframe developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset.

Among those newly diagnosed, the most commonly observed neurologic disorders were toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). Among patients with seizure, 34 of 74 (46%) had no prior history of seizure or epilepsy.

No patients reported with meningitis/encephalitis or myelopathy/myelitis referable to SARS-CoV-2 infection and 18 of 18 patients that underwent cerebrospinal fluid analyses were reverse transcription polymerase chain reaction negative for SARS-CoV-2.

In contrast to prior retrospective studies that focused on the conglomerate prevalence of non-specific neurologic symptoms (agitation, dysexecutive function, myalgia, dizziness, headache) along with neurologic diagnoses (e.g. stroke, seizures, Guillian-Barre syndrome etc.), we applied rigorous, standardized diagnostic criteria to identify the prevalence of specific neurologic diagnoses in a prospective fashion, the authors wrote.

Patients who were diagnosed with neurologic disorders after admission were significantly older, and more severely ill based on Sequential Organ Failure Assessment scores, intubation rates and acute renal failure rates. Additionally, patients who had neurologic disorders post-admission were more often diagnosed with stroke, hypoxic/ischemic brain injury, seizure, neuropathy, and myopathy.

New Study Shows Connection Between COVID-19 and Sleep Issues

Investigators from a web-based study conducted 4 weeks into national lockdowns in Israel found a high frequency of maternal clinical insomnia in recent months: 23% during the pandemic, compared to 11% in the 1-2 months prior to the pandemic.

They also found approximately 80% of mothers reported no change in their childs sleep quality, duration, and sleeping arrangement during the COVID-19 pandemic.

On the other hand, approximately 30% of these mothers reported a negative change in their childs sleep quality, as well as a decrease in sleep duration. There were also mothers who reported a positive change.

These findings suggest that the changes in sleep patterns during the COVID19 pandemic are varied and that no unified change for the worse should be expected, the authors wrote. Further consideration of changes in sleep within the family context during this ongoing crisis is needed.

Read the original:
How COVID-19 Influences Allergies, Neurology, and Sleep - Contagionlive.com

Artists can flourish after brain damage. What does this say about neurology and aesthetics? – aeon.co

Posted on by

You wouldnt expect a scientist, teacher or business leaders work to improve following a traumatic brain injury or the onset of a neurological disorder, but, oddly, that does sometimes seem to be the case for artists at least if youre willing to accept expert opinions on art. In this interview with Robert Lawrence Kuhn for the PBS series Closer to Truth, Anjan Chatterjee, professor of neurology at the University of Pennsylvania, explains how artistic proclivities and production can change and even improve with neurological disorder. Because of the brains complexity, there are myriad ways in which this phenomenon can potentially be made manifest, but, as Chatterjee elucidates, the answer lies in different constellations of brain systems becoming more prominent as others become subdued. And, as Kuhn and Chatterjee discuss, these experiences in both artists and observers raise intriguing questions at the frontiers of neurology and aesthetics.

See more here:
Artists can flourish after brain damage. What does this say about neurology and aesthetics? - aeon.co

Kinesiology researcher creates smart way to assess and track neurological function – UCalgary News

Posted on by

Testing someone for nerve damage is done manually by a clinician who determines what a patient can detect on their skin, most often using a specialized set of monofilaments or a tuning fork. It can be a long and uncomfortable process for the patient and the clinician. But using wearable technologies, Dr. Ryan Peters, PhD, in the Faculty of Kinesiology and member of the Hotchkiss Brain Institute at the Cumming School of Medicine, is developing new ways for performing neurological testing anytime, anywhere, and with greater accuracy.

Peters is a co-founder and chief science officer of Vibratus Inc., which is bringing these new neurological wearable technologies to market. You can think of Vibratus as your wearable neurologist, says Peters. He is pictured above, right, with members of his team.

Ryan Peters.

Adrian Shellard

Peters is creating a suite of devices and a software application, or app, to remotely monitor sensory and motor function of the foot sole, hand and other parts of the body. Vibratus technology uses vibration-emitting wearable devices, such as smartphones and watches, to measure a patients neural responses. This biometric data can be tracked and exchanged between the patient and their health-care provider at chosen intervals, enabling the worlds first virtual neurology clinic. The COVID-19 pandemic provides an ideal proving ground for such technologies, when in-person access to the neurologist can be more restrictive.

Patients with nerve damage have increased risk of injuries and falls, and yet months can go by before they can visit a neurologist to have their condition re-assessed. With this app, both the doctor and patient will quickly know if personalized treatment strategies are working or if they need to be adjusted, says Peters.

Peters says the technology is useful for nerve disorders such as peripheral neuropathy (nerve damage caused by conditions such as Type 2 diabetes or chemotherapy), peripheral nerve or spinal cord injuries, cerebral palsy, Parkinsons disease and stroke. The clinical tests that Vibratus is looking to improve upon are part of the standard neurological exam, making them useful for a broad range of neurological disorders.

Though still in the testing phase now, Peters plans to launch the app within the next year and has filed U.S. provisional patents for these technologies. It would be great to see our devices in the hands of everyone who does neurological testing. We have the potential to improve outcomes for people with neurological disorders while saving time and money for the health-care industry.

Vibratus will be the first startup business to come out of the Faculty of Kinesiologys new specialization in wearable technology, referred to as We-TRAC. Dr. Reed Ferber, PhD, who leads the We-TRAC program,says Peters has been a fantastic addition to the collaborative group.

He has shown success in obtaining grants, working with companies, and now as the first startup company to come out of We-TRAC, says Ferber. Peters says Ferber has been a tremendous mentor to him, and that it was Ferber who suggested he apply for the grants that are now supporting this endeavour.

As well as receiving a $101,500 grant from the National Sciences and Engineering Research Council of Canada, or NSERC, Peters received a $200,000 Life Science Fellowship from Innovate Calgary. These grants are for research and development funding, and the creation, entrepreneurship and talent development for emerging life science-based companies.

Innovate Calgary has supported our device prototyping activities and helped guide the business development for Vibratus which has been invaluable to us, says Peters.I appreciate the incredible support Im receiving from everyone.

Peters also collaborates closely with Drs. Tyler Cluff, Art Kuo and Nicole Culos-Reed in the Faculty of Kinesiology, along with his incoming students and the Vibratus team, includingco-foundersRaied Aburashed, who is the chief executive office and holds a Bachelor of Science degree from the Schulich School of Engineering at UCalgary, and Dr. Osman Darici, PhD, who is the chief technology officer and a postdoctoral scholar in the Faculty of Kinesiology at UCalgary.

For more information about the program, contact Dr. Ryan Peters, PhD.

We-TRACis developing the next generation of wearable tech experts and focusing on using wearable technology to revolutionize sport performance, health care and health research.

The University of Calgarys Faculty of Kinesiology is theNo. 1 ranked sport science school in North America and No. 7 globally, according to ShanghaiRanking.

Led by theHotchkiss Brain Institute,Brain and Mental Healthis one of six research strategies guiding the University of Calgary toward itsEyes Highgoals. The strategy provides a unifying direction for brain and mental health research at the university.

The University of Calgarys multidisciplinaryEngineering Solutions for Health: Biomedical Engineeringresearch strategy drives solutions to our most pressing health challenges in disease and injury prevention, diagnosis, and treatments. Our biomedical engineering researchers make a significant impact in our communities by extending lives, improving quality of life, promoting independence, and continuously improving the health system.

(Photos were taken prior to COVID-19)

Ryan Peters lab group in the Faculty of Kinesiology at the University of Calgary

Read the original post:
Kinesiology researcher creates smart way to assess and track neurological function - UCalgary News

Adamas Announces Agreement to Settle Patent Litigation with OsmoticaAs part of this agreement Adamas will acquire the global rights to OSMOLEX ER -…

Posted on by

EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc., Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, todayannouncedit hassigned an agreement tosettle its ongoing patent litigation with OsmoticaPharmaceutical US LLC, a subsidiary of OsmoticaPharmaceuticals plc.As a result of this agreement,both partieswilldrop their respective claims relating to thepatentlitigation,and Adamaswillacquire the global rightstoOSMOLEXERfor $7.5 million.The agreement is expected to closeearly in2021.

Adamas current portfolio consists of GOCOVRI (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy. OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment for Parkinsons disease and drug-induced extrapyramidal reactions in adult patients.

This settlement agreement removes any further litigation costs and related distraction for Adamas. The acquisition of OSMOLEX ER also expands our presence in Neurology which is part of our long-term growth strategy, said Neil F. McFarlane, Chief Executive Officer. The different FDA-approved indications and pharmacokinetic profiles for GOCOVRI and OSMOLEX ER allow for the treatment of distinct patient populations. We intend to leverage our commercial expertise to unlock the full potential of both products and serve more patients in the wider neurology community.

As part of the acquisition, Adamas will receiveexisting inventory and allrightstoOSMOLEX ER.Parties also entered a supply agreementin whichOsmoticawillbe the sole manufacturer ofOSMOLEXER.Both parties are working together toensurecontinuity ofproductsupplytopatients.

About GOCOVRI

GOCOVRI (amantadine) extended-release capsulesisthe first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF.

Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. Themost commonly observedadverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.

For more information about GOCOVRI, please visitwww.GOCOVRI.com.

About OSMOLEXER

OSMOLEX ER,(amantadine)extended-releasetablets, is FDA-approved for the treatment of Parkinsons disease and drug-induced extrapyramidal reactions in adult patients.OSMOLEX ER is contraindicated in patients with end-stage renal disease (i.e., creatinine clearance below 15 mL/min/1.73 m2). The most common adverse reactions reported in 5% of patients at the recommended dosage of immediate-release amantadine were nausea, dizziness/lightheadedness, and insomnia.

For more information about OSMOLEX ER, including the full Prescribing Information, please visit http://www.OSMOLEX.com

About Adamas

At Adamas our vision is clear - to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visitwww.adamaspharma.com.

Forward-looking statements

Statements contained in this press release regarding matters that may occur in the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas expectationsregarding the expected timing of the closing of the transaction with Osmotica. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. Forexample, the completion of the transaction is subject to closing conditions, which if not met or waived, would cause the transaction not to close. Other risks relating to Adamas may be found inAdamas Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020, particularly under the caption Risk Factors. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Contact:

MediaSarah MathiesonVice President of Corporate Communications510-450-3528smathieson@adamaspharma.com

InvestorsPeter VozzoManaging Director, Westwicke443-213-0505peter.vozzo@westwicke.com

View original post here:
Adamas Announces Agreement to Settle Patent Litigation with OsmoticaAs part of this agreement Adamas will acquire the global rights to OSMOLEX ER -...

Effect of a passive hip exoskeleton on walking distance in neurological patients – DocWire News

Posted on by

This article was originally published here

Assist Technol. 2021 Jan 22. doi: 10.1080/10400435.2021.1880494. Online ahead of print.

ABSTRACT

Severe neurodegenerative diseases such as Parkinsons disease or multiple sclerosis and acute events like stroke, spinal cord injuries or other related pathologies have been shown to negatively impact the central and peripheral nervous systems, thus causing severe impairments to mobility. The development and utilisation of exoskeletons as rehabilitation devices has shown good potential for improving patients gait function. Ten older adults (age: 68.9 9.2 yrs; height: 1.65 0.08 m. mass: 71.6 11.0 kg) affected by neurological diseases impacting their gait function completed a 10-session gait training protocol where they walked for 10 minutes wearing a passive exoskeleton assisting hip flexion, namely Exoband. Results showed that participants walked a significantly longer distance in the last session of training with respect to the first session (453.1178.8m vs 392.4135.1m; respectively). This study indicates the potential of Exoband as an effective tool for gait rehabilitation in patients with neurological diseases. Wearable, lightweight and low-cost devices such as the one involved in this work have the potential to improve walking distance in patients.

PMID:33481693 | DOI:10.1080/10400435.2021.1880494

More here:
Effect of a passive hip exoskeleton on walking distance in neurological patients - DocWire News

Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets – Daily Local…

Posted on by

EXTON, Pa., Jan. 29, 2021 /PRNewswire/ --Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering, Launch Dynamix. This innovative, independent service provides monthly benchmarking of newly launched products for the first eighteen months of commercial availability.

This is augmented by a quarterly deep dive into promotional activity, messaging, drivers of use, barriers to uptake, patient types, market access landscape, and degree of disruption surrounding the newly launched product including a mix of both quantitative and qualitative feedback. Clients subscribed to this service received their first monthly pulse on January 15, 2021, including data benchmarking the current launch to relevant historical market entrants at similar post-entry timings.

In rheumatology, Spherix is currently tracking the entry of both Novartis' Cosentyx and Eli Lilly's Taltz in non-radiographic axial spondylarthritis (nr-axSpA), which were approved within weeks of each other in June of last year. Data on the key performance indicators (KPIs), provided in the January publication, are compared to the performance of UCB's Cimzia, which was the first biologic/advanced systemic agent to gain FDA approval for nr-axSpA in March of 2019.

With regard to psoriatic arthritis (PsA), Spherix's new service is available for Janssen's Tremfya, with KPIs benchmarked to Cosentyx, Taltz, Amgen's Otezla, and Pfizer's Xeljanz. Pending FDA approval, Spherix also plans to cover AbbVie's Rinvoq in both ankylosing spondylitis (AS) and PsA, Xeljanz for the treatment of AS, and AstraZeneca's anifrolumab for the treatment of systemic lupus erythematosus.

Inaugural Launch Dynamix coverage in gastroenterology includes tracking and trending of Janssen's Stelara for the treatment of ulcerative colitis (UC), benchmarking the entry of the IL-12/23 inhibitor to the respective Crohn's disease launch, as well as the launch of Xeljanz for the treatment of UC.

In neurology, Spherix is currently covering the launches of Novartis' Kesimpta and BMS' Zeposia, with appropriate benchmarked KPIs to Genentech's Ocrevus, Novartis' Mayzent, EMD Serono's Mavenclad, and Biogen's Vumerity. Pending approval, Spherix will also cover the launch of Janssen's ponesimod, which is expected to be available in the Spring of 2021.

In an area of significant unmet need, the lupus nephritis market is poised for a massive shift with recent drug approvals for GSK's Benlysta (also approved for systemic lupus erythematosus) and Aurinia Pharmaceuticals' Lupkynis. The study will include responses from both nephrologists and rheumatologists, with the first pulse available in February.

Other launches on Spherix's radar with planned 2021 coverage (pending approval) include:

"We are really excited to be able to bring this level of launch detail to our clients," says Lynn Price, Vice President of Strategy and Innovation at Spherix. "The rapid turn-around from fielding to publication and the monthly cadence coupled with quarterly deep-dives provides those with assets in this market or with near-term plans to enter it the perfect tool to keep their finger on the pulse."

About Launch Dynamix

Launch Dynamix is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into patient types initiated, brand perceptions, promotional activity, and drivers and barriers to uptake. The service is offered on a brand-by-brand basis.

Learn more about our services here.

About Spherix Global Insights

Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:

Kristen Henn, Business Development Manager

Email:info@spherixglobalinsights.com

http://www.spherixglobalinsights.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-global-insights-introduces-new-service-focusing-on-recent-launches-in-expanding-immunology-nephrology-and-neurology-markets-301217950.html

SOURCE Spherix Global Insights

Go here to read the rest:
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets - Daily Local...

Interventional Neurology Devices Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 – Aerospace Journal

Posted on by

Interventional Neurology Devices Market Forecast 2020-2026

The Global Interventional Neurology Devices Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Interventional Neurology Devices Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://industrygrowthinsights.com/request-sample/?reportId=133707

The Report Covers the Following Companies:AbbottDePuy SynthesMedtronicStrykerTerumoAcandisBayerBoston ScientificBiosensors InternationalevonosMerit Medical SystemsMicroPort ScientificNeurosignPenumbraSpiegelbergSurtex Instruments

By Types:by ProductsCarotid Artery Angioplasty and StentingCarotid Artery StentsEmbolic Protection SystemsBalloon Occlusion DevicesAneurysm Coiling and Embolization DevicesFlow Diversion DevicesLiquid Embolic DevicesEmbolic coilsMicr-Support DevicesMicrocathetersby TechniquesAngioplasty & StentingNeurothrombectomyPre-operative Tumor EmbolizationVertebroplastyStroke Therapy

By Applications:Arteriovenous Malformation and FistulasCerebral AneurysmsSchemic StrokesIntracranial Atherosclerotic Disease

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=133707

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Interventional Neurology Devices Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=133707

About Industrygrowthinsights:Industrygrowthinsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://Industrygrowthinsights.com

Read more here:
Interventional Neurology Devices Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - Aerospace Journal

‘I felt symptoms of my paralysing illness before getting married – but didn’t tell my fiance’ – Telegraph.co.uk

Posted on by

Must you share your medical secrets with the person you are about to marry? Xavier Alford wishes he had. In 2007, the filmmaker was all set to wed his fiance, Anna, with whom he already had a two-year-old daughter, when he noticed a peculiar tingling in the big toe of his left foot. Around the same time, he realised he couldnt lift the toeup and his walking became slightly off-kilter. He was getting cramps in his calf muscles, as well as a strange quivering sensation in his lower leg. But Alford kept the symptoms to himself. He married Anna, and they soon had a son.

I just didnt want to go there, remembers Alford, 42, who lives in Bath with his wife and their now teenage children. I felt it would be opening a medical Pandoras box. I didnt Google anything, [but] in my heart of hearts I knew it was potentially quite serious.

The feeling in his leg continued, on and off, and a few years later he noticed tingling in his fingers when trying to sleep. Soon, uncontrollable shaking meant he was unable to hold a camera for too long. He saw his GP, who gave him a real telling off for ignoring the problem.

After a series of tests, Alford was diagnosed with multifocal motor neuropathy (MMN), a super-rare neurological illness related to the more commonGuillain-Barr syndrome, in which the immune system attacks the nerves in Alfords case, spreading through his arms and legs, and slowly paralysing parts of his body. Some unluckysufferers ofGuillain-Barr syndrome developlocked-in syndrome the nightmarish state of being fully conscious but paralysed from the neck down, able to communicate only through his eyes, depicted in the book and film The Diving Bell and the Butterfly. This is unlikely to happen to Alford, but because his condition is so rare, he has no idea just how unlikely.

Alfordentered a period of denial after his diagnosis. That was a horrible walk home, really horrendous. I wanted to try and brush this illness under the carpet. Because in some weird way, I thought it might disappear if I carried on doing that, he recalls.

Eventually, Alford confronted his diagnosis in the only way he knew how by making a film about it. In the new documentary,Locked In: Breaking the Silence, airing on BBC Four tonight, and on the British Film Institute website from today, Alford meets others whose lives have been transformed by the unpredictable condition, and grapples with his oncoming paralysis a fact he has kept largely secret until now.

Currently, he can move around independently, but his arms are weak and hard to control, making it difficult to take the bins out, for example, and it is becoming near-impossible for the filmmaker to hold a camera. As he learns more about his disease, we see the momenthe admits to his wife that he had hadsymptoms for years before he saw a doctor. I kept it to myself, and Im sorry I did that, because I should have definitely been open with you, he tells her.

And what did Anna make of that, I ask now? She just accepted it, she said: Its OK. There was no anger. It was a much bigger thing in my head than it was for her. I dont think shed have suddenly said, Im not marrying you, or, I dont love you any more.

Alford rarely discusses the condition with his children. It was only while making the film that his son, Louis, asked if MMN is fatal (probably not, although it can kill in rare cases), and whether he might inherit it (Alfords children are no more likely than the average person to develop the condition).

The unpredictability of the disease is what makes it most frightening and the suddenness with which a locked-inepisode can strike. In his film, Alford meets Scott, 45, an Australian coach driver living in Britain, who was backpacking around Europe in 2016, seemingly healthy, when he noticed a tingling in his fingers (a common first sign of Guillain-Barr).

See the original post:
'I felt symptoms of my paralysing illness before getting married - but didn't tell my fiance' - Telegraph.co.uk

Neurology Devices Market | Increasing Prevalence Of The Neurological Disorders to boost the Market Growth | Technavio – Yahoo Finance

Posted on by

Technavio has been monitoring the neurology devices market and it is poised to grow by $ 9.02 bn during 2020-2024, progressing at a CAGR of almost 12% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005783/en/

Technavio has announced its latest market research report titled Global Neurology Devices Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

What are the major trends in the market? Increasing adoption of wearable neurology devices is a major trend driving the growth of the market

At what rate is the market projected to grow? The year-over-year growth for 2020 is estimated at 11.50% and the incremental growth of the market is anticipated to be $ 9.02 bn

Who are the top players in the market? Abbott Laboratories, B. Braun Melsungen AG, Becton, Dickinson and Co., Boston Scientific Corp., Johnson & Johnson Services Inc., Medtronic Plc, MicroPort Scientific Corp., Nihon Kohden Corp., Penumbra Inc., and Stryker Corp., are some of the major market participants

What is the key market driver? The increasing prevalence of the neurological disorders is one of the major factors driving the market

How big is the North America market? The North America region will contribute 42% of the market share

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, B. Braun Melsungen AG, Becton, Dickinson and Co., Boston Scientific Corp., Johnson & Johnson Services Inc., Medtronic Plc, MicroPort Scientific Corp., Nihon Kohden Corp., Penumbra Inc., and Stryker Corp. are some of the major market participants. The increasing prevalence of the neurological disorders will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Story continues

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neurology Devices Market 2020-2024: Segmentation

Neurology Devices Market is segmented as below:

Product

Geography

Asia

Europe

North America

ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40120

Neurology Devices Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neurology devices market report covers the following areas:

Neurology Devices Market Size

Neurology Devices Market Trends

Neurology Devices Market Industry Analysis

This study identifies increasing adoption wearable neurology devices as one of the prime reasons driving the neurology devices market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neurology Devices Market 2020-2024: Key Highlights

CAGR of the market during the forecast period 2020-2024

Detailed information on factors that will assist neurology devices market growth during the next five years

Estimation of the neurology devices market size and its contribution to the parent market

Predictions on upcoming trends and changes in consumer behavior

The growth of the neurology devices market

Analysis of the markets competitive landscape and detailed information on vendors

Comprehensive details of factors that will challenge the growth of neurology devices market vendors

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Neurostimulation devices - Market size and forecast 2019-2024

Interventional neurology devices - Market size and forecast 2019-2024

Neurosurgery devices - Market size and forecast 2019-2024

Cerebrospinal fluid management devices - Market size and forecast 2019-2024

Others - Market size and forecast 2019-2024

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America - Market size and forecast 2019-2024

Europe - Market size and forecast 2019-2024

Asia - Market size and forecast 2019-2024

ROW - Market size and forecast 2019-2024

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Technological advances and new product launches

Strong penetration of wearable neurology devices

Growing medical tourism in emerging economies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Abbott Laboratories

B. Braun Melsungen AG

Becton, Dickinson and Co.

Boston Scientific Corp.

Johnson & Johnson Services Inc.

Medtronic Plc

MicroPort Scientific Corp.

Nihon Kohden Corp.

Penumbra Inc.

Stryker Corp.

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005783/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

View original post here:
Neurology Devices Market | Increasing Prevalence Of The Neurological Disorders to boost the Market Growth | Technavio - Yahoo Finance

Impact of Covid-19 Global Neurology EMR Software Market (2020 To 2027) | NueMD, Greenway Health, AdvancedMD, Athenahealth, PrognoCIS by Bizmatics -…

Posted on by

Global Neurology EMR Software Market Research report 2020 provides detailed analysis of industry status and outlook of major regions based on of key players, countries, product types, and end industries. This research report offers the overall analysis of the segments such as market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. Global Neurology EMR Software market research report consist information according to the manufacturers, regions, type, and application.

According to the report, the Neurology EMR Software market is set to grow at a CAGR of xx% over the forecast period (2019-2027) and exceed a value of US$ XX by the end of 2027. The global Neurology EMR Software market offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status.

Leading companies reviewed in the Neurology EMR Software Market report are: NueMDGreenway HealthAdvancedMDAthenahealthPrognoCIS by BizmaticsKareoAprima EHR SoftwareAzalea HealtheClinicalWorksCureMDChartLogic EHR SuiteDocLinks

Available Sample Report in PDF Version along with Graphs and Figures@ https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#sample

Covid-19 pandemics create the negative impact on the majority of the developed and developing economies around the globe. Report covers the income impact investigation, interruptions and new open doors in the gracefully chain, overhauled merchant scene blend, new open doors mapping, and others. Also offers the various solutions and recovery options to solve this COVID-19 pandemic.

Global Neurology EMR Software Market Segmentation by Type: Type IType II

Global Neurology EMR Software Market Segmentation by Applications:Medical FacilitiesResearch InstitutesOthers

Market Segmentation, By regions:

The report covers different geographical areas that are studied systematically and other profitable scenarios are offered to assist new entrants, leading market players, and investors to regulate emerging economies.

The global Neurology EMR Software research report focuses on the potential tradeoff between the quality and price; industry stakeholders which are actively leveraging the potential across the various applications, such as product design, quality control, maintenance, as well as consumer engagement among others.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#inquiry

Important Points Covered by Report:

Access Full Report, here: https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/

There are 13 Chapters to display the Global Neurology EMR Software market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Neurology EMR Software Research Findings and Conclusion, Appendix, methodology and data source.

Read more:
Impact of Covid-19 Global Neurology EMR Software Market (2020 To 2027) | NueMD, Greenway Health, AdvancedMD, Athenahealth, PrognoCIS by Bizmatics -...

‘Landmark’ Study Pushed Detection of Covert Consciousness in TBI – Medscape

Posted on by

Compelling advances in the ability to detect signs of consciousness in unconscious patients who have experienced traumatic brain injury (TBI) are leading to unprecedented changes in the field. There is now hope of improving outcomes and even sparing lives of patients who may otherwise have been mistakenly assessed as having no chance of recovery.

A recent key study represents a tipping point in the mounting evidence of the ability to detect"covert consciousness" in patients with TBI who are in an unconscious state. That research, published in The New England Journal of Medicine (NEJM) in June 2019, linked the promising signals of consciousness in comatose patients, detected only on imaging, with remarkable outcomes a year later.

"This was a landmark study," said Brian L. Edlow, MD, in a presentation on the issue of covert consciousness during the American Neurological Association's 2020 virtual annual meeting.

"Importantly, it is the first compelling evidence that early detection of covert consciousness also predicts 1-year outcomes in the Glasgow Outcome Scale Extended (GOSE), showing that covert consciousness in the ICU appears to be relevant for predicting long-term outcomes," said Edlow, who is associate director of the Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, in Boston.

The researchers showed that 15% of unconscious patients with acute brain injury in the study exhibited significant brain activity on EEG in response to stimuli that included verbal commands such as envisioning that they are playing tennis.

Although other studies have shown similar effects with task-based stimuli, the NEJM study further showed that a year later, the patients who had shown signs of covert consciousness, also called "cognitive motor dissociation" (CMD), were significantly more likely to have a good functional outcome, said the study's senior author, Jan Claassen, MD, director of critical care neurology at Columbia University, in New York City, who also presented during the ANA session.

"Importantly, a year later after injury, we found that 44% of patients with CMD and only 14% of non-CMD patients had a good functional outcome, defined as a GOSE score indicating a state where they can at least take care of themselves for 8 hours in a day," he said.

"[Whether] these patients in a CMD state represent a parallel state or a transitory state on the road to recovery remains to be shown," he said.

Jennifer Frontera, MD, a professor in the Department of Neurology at NYU Langone in New York City and co-moderator of the session, agreed that the research is "remarkable."

"Also, it is practical, since many could potentially apply and validate his algorithms, since EEG technology is portable and widely available," she told Medscape Medical News.

The research has helped push forward recommendations on the treatment of unconscious patients, Edlow said.

"This has led to a sea change in our field just over the last 2 years, with multiple guidelines published suggesting that it may be time for us to consider incorporating task-based fMRI and EEG techniques into our clinical assessment of patients with disorders of consciousness," Edlow said.

Among those updating their recommendations was the American Academy of Neurology, which revised guidelines on practice parameters for patients in a persistent vegetative state. Those guidelines had not been updated since 1995.

Although concluding that "no diagnostic assessment procedure had moderate or strong evidence for use," the guidelines acknowledge that "it is possible that a positive electromyographic (EMG) response to command, EEG reactivity to sensory stimuli, laser-evoked potentials, and the Perturbational Complexity Index can distinguish a minimally conscious state from vegetative state/unresponsive wakefulness syndrome (VS/UWS)."

Earlier this year, the European Academy of Neurology (EAN) followed suit with updated guidelines of its own.

In the EAN guideline, the academy's Panel on Coma, Disorders of Consciousness, recommends that task-based fMRI, EEG, and other advanced assessments be performed as part of a composite assessment of consciousness and that a patient's best performance or highest level of consciousness on any of those tests should be a reflection of their diagnosis, Edlow explained.

"What this means is that our field is moving toward a multimodal assessment of consciousness in the ICU as well as beyond, in the subacute to chronic setting, whereby the behavioral exam, advanced DG, and advanced MRI methods all also contribute to the diagnosis of consciousness," he said.

The gold standard for assessment of disorders of consciousness is the Coma Recovery Scale Revised, with 25-item scale for diagnosis, prediction of outcome, and assess potential treatment efficacy.

But much uncertainty can remain despite the assessment, Claassen said.

"Behavioral assessments of patients with acute brain injury are challenging because examinations fluctuate, and there's variability between assessors," he said. "Nevertheless, patients and their families demand guidance from us."

Edlow pointed out that the largest study to date of the causes of death among patients with TBI in the ICU underscores the need for better assessments.

The study of more than 600 patients at six level l trauma centers in Canada showed that 70% of patients who died in the ICU from TBI did so as the result of the withdrawal of life-sustaining therapy.

However, only about a half (57%) had an unreactive pupil, and only about a quarter (23.7%) had evidence of herniation on CT, findings that are commonly associated with a poor prognosis.

"What emerges from this is that the manner in which the clinicians communicated the prognosis to families was a primary determinant of decisions to withdraw life-sustaining therapy," Edlow said.

Edlow added a word of caution that the science is still far from perfect. He noted that for 25% of healthy patients who are given a motor imagery task, neuroimaging might not show a response, implying that the lack of a signal may not be conclusive.

He described the case of a patient who was comatose at the time she was scanned on day 3 after injury and who showed no responses to language, music, or motor imagery during the MRI, yet a year later, she was functionally independent, back in the workforce, and had very few residual symptoms from her trauma.

"So if a patient does not show a response, that does not prove the patient is not conscious, and it does not prove that the patient is likely to have a poor outcome," Edlow said.

Such cases underscore the need for more advances in understanding the inner workings of brain injury.

Heeding that call, Edlow and his colleagues are embarking on a trial of the effects of intravenous methylphenidate in targeting the stimulation of dopaminergic circuits within the subcortical ascending arousal network in patients with severe brain injuries.

"The scientific premise of the trial is that personalized brain network mapping in the ICU can identify patients whose connectomes are amenable to neuromodulation," Edlow and his colleague report in an article in Neurocritical Care.

The trial, called STIMPACT (Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness), is part of the newly launched Connectome-based Clinical Trial Platform, which the authors describe as "a new paradigm for developing and testing targeted therapies that promote early recovery of consciousness in the ICU."

Such efforts are essential, given the high stakes of TBI outcomes, Edlow said.

"Let's be clear about the stakes of an incorrect prognosis," he said. "If we're overly pessimistic, then a patient who could have potential for meaningful recovery will likely die in our ICU. On the other hand, if we are overly optimistic, then a patient could end up in a vegetative or minimally conscious state that he or she may never have found to be acceptable," he said.

Some ethicists in the field are recommending that patients be given access to the advanced techniques as a civil right, similar to the rights described in the Convention on the Rights of Persons With Disabilities, which was adopted by the United Nations in 2008, Edlow noted.

"So the question that we as clinicians are going to face moving forward from an ethical standpoint is, if we have access to these techniques, is it an ethical obligation to offer them now?" he said.

Edlow underscored the need to consider the reality that "there are profound issues relating to resource allocation and access to these advanced techniques, but we're going to have to consider this together as we move forward."

Edlow has received funding from the National Institutes of Health. Claassen is a minority shareholder with ICE Neurosystems. Frontera has disclosed no relevant financial relationships.

ANA 2020: 145th Annual Meeting of the American Neurological Association: Abstract 535, presented October 9, 2020.

For more Medscape Neurology news, join us on Facebook and Twitter.

Read the rest here:
'Landmark' Study Pushed Detection of Covert Consciousness in TBI - Medscape

COVID-19 Pandemic and Neurological Disease: A Critical Review of the Existing Literature – DocWire News

Posted on by

This article was originally published here

Hosp Pract Res. 2020 Summer;5(3):81-86.

ABSTRACT

Most of what we know about the coronavirus disease 2019 (COVID-19) is limited to what we know about severe acute respiratory syndrome (SARS) and COVID-19s epidemiology, fatality, and acute care. However, infection with COVID-19 may also involve the central nervous system (CNS), which may or may not be due to a multi-organ injury. Our aim in this paper is to briefly summarize the main aspects of the growing literature on neurological manifestations of the COVID-19 infection. As such, after mentioning some general background on the economic and medical implications of the pandemic on individuals, the healthcare system, and the society, we summarize some common aspects of the published literature on neurological manifestations of the COVID-19 infection. We also highlight the existing gaps in the literature, which requires additional work. The most common neurological manifestation of COVID-19 infection is an olfactory deficit. However, it is still unknown if it is inflammatory or degenerative in nature. Still, the incidence of neurological complications, and also their mechanisms and treatments are unknown. This literature is predominantly composed of opinions and reviews rather than original articles, so the patients data are not used for a majority of the studies. Multi-center studies that not only conduct chest CT or MRI but also brain CT or MRI are needed. Randomized trials are still required on the management of acute and chronic neurological conditions due to COVID-19 infection. Cohort studies may also determine the natural history of the conditions and factors that are prognostic. Furthermore, while disparities in COVID-19 infections are known, inequalities in neurological manifestations are unknown. Besides this, the efficacy of specific treatments on CNS involvement is still unknown. We will discuss the health care needs of patients with chronic neurological conditions. We Included a few recommendations for practice and further research at the end of this paper.

PMID:33094214 | PMC:PMC7577209

Go here to see the original:
COVID-19 Pandemic and Neurological Disease: A Critical Review of the Existing Literature - DocWire News

Study finds significant link between PM2.5 pollution and neurological disorders in US – Green Car Congress

Posted on by

PM2.5 pollution was significantly associated with an increased risk of hospital admissions for several neurological disorders, including Parkinsons disease, Alzheimers disease, and other dementias, in a long-term study of more than 63 million older US adults, led by researchers at Harvard T.H. Chan School of Public Health.

The study, conducted with colleagues at Emory Universitys Rollins School of Public Health and Columbia Universitys Mailman School of Public Health, is the first nationwide analysis of the link between fine particulate (PM2.5) pollution and neurodegenerative diseases in the US. The researchers leveraged an unparalleled amount of data compared to any previous study of air pollution and neurological disorders.

The open-access study is published in the journal The Lancet Planetary Health.

The 2020 report of the Lancet Commission on dementia prevention, intervention, and care has added air pollution as one of the modifiable risk factors for these outcomes. Our study builds on the small but emerging evidence base indicating that long-term PM2.5 exposures are linked to an increased risk of neurological health deterioration, even at PM2.5 concentrations well below the current national standards.

Xiao Wu, doctoral student in biostatistics at Harvard Chan School and co-lead author

Researchers looked at 17 years worth (2000-2016) of hospital admissions data from 63,038,019 Medicare recipients in the US and linked these with estimated PM2.5 concentrations by zip code.

Taking into account potential confounding factors such as socioeconomic status, they found that, for each 5 microgram per cubic meter of air (g/m3) increase in annual PM2.5 concentrations, there was a 13% increased risk for first-time hospital admissions both for Parkinsons disease and for Alzheimers disease and related dementias.

This risk remained elevated even below supposedly safe levels of PM2.5 exposure, which, according to current US Environmental Protection Agency standards, is an annual average of 12 g/m3 or less.

Women, white people, and urban populations were particularly susceptible, the study found. The highest risk for first-time Parkinsons disease hospital admissions was among older adults in the northeastern US For first-time Alzheimers disease and related dementias hospital admissions, older adults in the Midwest faced the highest risk.

Our US-wide study shows that the current standards are not protecting the aging American population enough, highlighting the need for stricter standards and policies that help further reduce PM2.5 concentrations and improve air quality overall.

Antonella Zanobetti, principal research scientist in Harvard Chan Schools Department of Environmental Health and co-senior author

This study was supported by the Health Effects Institute (4953-RFA14-3/16-4), the National Institute of Environmental Health Sciences (NIEHS R01 ES024332, R01 ES028805, R21 ES028472, P30 ES009089, P30 ES000002), the National Institute on Aging (NIA/NIH R01 AG066793-01, P50 AG025688), and the HERCULES Center (P30ES019776). Research described in this article was done under contract to the Health Effects Institute, an organization jointly funded by the US Environmental Protection Agency (assistance award number R-83467701) and some motor vehicle and engine manufacturers.

Resources

Liuhua Shi, Xiao Wu, Mahdieh Danesh Yazdi, Danielle Braun, Yara Abu Awad, Yaguang Wei, Pengfei Liu, Qian Di, Yun Wang, Joel Schwartz, Francesca Dominici, Marianthi-Anna Kioumourtzoglou, Antonella Zanobetti (2020) Long-term effects of PM2.5 on neurological disorders in the American Medicare population: a longitudinal cohort study, The Lancet Planetary Health doi: 10.1016/S2542-5196(20)30227-8

View post:
Study finds significant link between PM2.5 pollution and neurological disorders in US - Green Car Congress